Immunocore Holdings plc (IMCR) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 14 analysts62.6% Below Target
IMCR trades 62.6% below Wall Street's consensus target of $46.50.
Current Price$28.60
Average Target$46.50
Target
Current
Low$38.00
Median$46.50
High$55.00
Analyst Target Range
Forward P/E239.5x
(High Premium)
PEG Ratio—
Implied Growth+133.6%
(High Growth)
Analyst Spread36.6%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes IMCR achieves its forward estimates and maintains a stable P/E multiple of 239.5x. This scenario reflects the blended consensus of 14 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
IMCR Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Immunocore Holdings plc (IMCR) has a Wall Street consensus price target of $46.50, based on estimates from 14 covering analysts. With the stock currently trading at $28.60, this represents a potential upside of +62.6%. The company has a market capitalization of $1.45B.
Analyst price targets range from a low of $38.00 to a high of $55.00, representing a 37% spread in expectations. The median target of $46.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, IMCR trades at a trailing P/E of -54.0x and forward P/E of 239.5x. Analysts expect EPS to grow +133.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+88.1%
Industry Consensus
Avg Forward P/E
9.3x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KYMRKymera Therapeutics, Inc. | $7.4B | $90.43 | $112.60 | +24.5% | Buy | — | 26 |
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
 AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
 MGNXMacroGenics, Inc. | $263M | $4.13 | $6.00 | +45.3% | Buy | — | 22 |
 FATEFate Therapeutics, Inc. | $244M | $2.09 | $5.50 | +163.2% | Buy | — | 31 |
 ADCTADC Therapeutics S.A. | $139M | $1.09 | $3.50 | +221.1% | Hold | — | 12 |
 GILDGilead Sciences, Inc. | $153.7B | $123.76 | $161.81 | +30.7% | Buy | — | 58 |
 EXELExelixis, Inc. | $13.2B | $51.91 | $47.33 | -8.8% | Buy | 14.7x | 32 |
 IDYAIDEAYA Biosciences, Inc. | $2.7B | $31.23 | $58.67 | +87.9% | Buy | — | 25 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
IMCR — Frequently Asked Questions
Quick answers to the most common questions about buying IMCR stock.
What is the IMCR stock price target for 2026?
The consensus Wall Street price target for IMCR is $46.5, representing 62.6% upside from the current price of $28.6. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is IMCR a buy, sell, or hold?
IMCR has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $46.5 implies 62.6% upside from current levels.
Is IMCR stock overvalued or undervalued?
At a forward P/E of 239.531x, IMCR trades at a premium valuation. The consensus price target of $46.5 (62.6% upside) suggests analysts still see growth justifying the multiple.
How high can IMCR stock go?
The most bullish Wall Street analyst has a price target of $55 for IMCR, while the most conservative target is $38. The consensus of $46.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover IMCR stock?
IMCR is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IMCR stock forecast?
The 12-month IMCR stock forecast based on 14 Wall Street analysts shows a consensus price target of $46.5, with estimates ranging from $38 (bear case) to $55 (bull case). The median consensus rating is "Buy".
What is IMCR's forward P/E ratio?
IMCR trades at a forward P/E ratio of 239.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy IMCR stock?
Wall Street analysts are very optimistic on IMCR, with a "Buy" consensus rating and $46.5 price target (62.6% upside). 9 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IMCR price targets vary so much?
IMCR analyst price targets range from $38 to $55, a 37% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $46.5 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare